Investor Presentaiton

Principal Secondary Endpoints Hazard ratio (95% CI)+ 0.93 (0.81, 1.07) Principal secondary endpoints did not meet multiplicity-adjusted statistical significance for superiority* asceND D DIALYSIS MACE (superiority) asceND ND NON-DIALYSIS MACE (superiority) Hazard ratio (95% CI)+ 1.03 (0.89, 1.19) MACE + thromboembolic events (DVT, PE, VAT) 0.88 (0.78, 1.00) MACE + thromboembolic events (DVT, PE, VAT) 1.06 (0.93, 1.22) MACE + hospitalization for heart failure 0.97 (0.85, 1.11) MACE + hospitalization for heart failure 1.09 (0.95, 1.24) Adjusted Mean Treatment Difference daprodustat-ESA (95% CI)* Hazard ratio (95% CI)$ -9.1 (-18.4, 0.2) On-treatment average monthly IV iron dose (mg) from baseline to Week 52 CKD progression (40% decline in eGFR OR ESRD, i.e., chronic dialysis, not initiating dialysis when indicated or kidney transplant) 0.98 (0.84, 1.13) *Holm-Bonferroni multiplicity adjustment used for principal secondary endpoints. *HR estimated using a Cox proportional hazards regression model with treatment group, dialysis type (ASCEND-D) or baseline ESA use (ASCEND-ND) and region as covariates. *Based on an ANCOVA model with terms for treatment, baseline monthly IV iron dose, dialysis type and region; $Subdistribution hazard ratio estimated using Fine & Gray's proportional subdistribution hazard regression model with treatment group, baseline ESA use, and region as covariates. A HR <1 indicates a lower risk with daprodustat compared with ESA/darbepoetin alfa. Cl, confidence interval; CKD, chronic kidney disease; DVT, deep vein thrombosis; eGFR, estimated glomerular filtration rate; ESA, erythropoiesis-stimulating agent; ESRD, end stage renal disease; HR, hazard ratio; IV, intravenous; MACE, major adverse cardiovascular event; PE, pulmonary embolism; VAT, vascular access thrombosis. 15

View entire presentation